Role of bone-forming agents in the management of osteoporosis

被引：28
|
作者：
McClung, Michael R. [1 ,2 ]
机构：
[1] Oregon Osteoporosis Ctr, Portland, OR 97225 USA
[2] Australian Catholic Univ, Mary MacKillop Ctr Hlth Res, Melbourne, Vic, Australia
来源：
AGING CLINICAL AND EXPERIMENTAL RESEARCH | 2021年 / 33卷 / 04期
基金：
美国国家卫生研究院;
关键词：
Osteoporosis; Osteoanabolic; Abaloparatide; Romosozumab; Teriparatide; Sequence;
D O I：
10.1007/s40520-020-01708-8
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
Recent evidence confirms the superiority of osteoanabolic therapy compared to anti-remodeling drugs for rapid improvement in bone density and fracture risk reduction, providing strong justification for the use of these anabolic agents as the initial therapy in high-risk patients, to be followed by anti-remodeling therapy. This review will highlight the results of recent studies and define the current status of osteoanabolic therapy for osteoporosis.
引用
收藏
页码：775 / 791
页数：17
相关论文
共 50 条
  • [21] Bone Material Properties in Actively Bone-Forming Trabeculae in Postmenopausal Women With Osteoporosis After Three Years of Treatment With Once-Yearly Zoledronic Acid
    Gamsjaeger, Sonja
    Buchinger, Birgit
    Zwettler, Elizabeth
    Recker, Robert
    Black, Dennis
    Gasser, Juerg A.
    Eriksen, Erik F.
    Klaushofer, Klaus
    Paschalis, Eleftherios P.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2011, 26 (01) : 12 - 18
  • [22] Inactivation of estrogen receptor α in bone-forming cells induces bone loss in female mice
    Maatta, Jorma A.
    Buki, Kalman G.
    Gu, Guoliang
    Alanne, Maria H.
    Vaaraniemi, Jukka
    Liljenback, Heidi
    Poutanen, Matti
    Harkonen, Pirkko
    Vaananen, Kalervo
    FASEB JOURNAL, 2013, 27 (02) : 478 - 488
  • [23] Latest on Anabolic Agents for Osteoporosis Treatment
    di Filippo, Luigi
    Rosen, Clifford J.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2024, 53 (04) : 513 - 523
  • [24] Osteophytes, Enthesophytes, and High Bone Mass A Bone-Forming Triad With Potential Relevance in Osteoarthritis
    Hardcastle, Sarah A.
    Dieppe, Paul
    Gregson, Celia L.
    Arden, Nigel K.
    Spector, Tim D.
    Hart, Deborah J.
    Edwards, Mark H.
    Dennison, Elaine M.
    Cooper, Cyrus
    Williams, Martin
    Smith, George Davey
    Tobias, Jon H.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 (09) : 2429 - 2439
  • [25] Osteoanabolic Agents for Osteoporosis
    Haas, Andrea V.
    LeBoff, Meryl S.
    JOURNAL OF THE ENDOCRINE SOCIETY, 2018, 2 (08): : 922 - 932
  • [26] GLUCOCORTICOIDS AND BONE METABOLISM: IDENTIFYING NEW PLAYERS IN THE NEGATIVE IMPACT OF GLUCOCORTICOIDS ON BONE-FORMING CELLS
    Ali, Dalia
    Madsen, Martin R.
    Kassem, Moustapha
    Mandrup, Susanne
    Rauch, Alexander
    JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2024, 79 (05): : 3 - 3
  • [27] Biological agents in management of osteoporosis
    Sri Harsha Tella
    J. Christopher Gallagher
    European Journal of Clinical Pharmacology, 2014, 70 : 1291 - 1301
  • [28] Suboptimal Level of Bone-Forming Cells in Advanced Cirrhosis are Associated with Hepatic Osteodystrophy
    Bihari, Chhagan
    La, Deepika l
    thakur, Monika
    Sukriti, Sukriti
    Mathur, Dhananjay
    Patil, Anupama G.
    Anand, Lovkesh
    Kumar, Guresh
    Sharma, Shvetank
    Thapar, Shalini
    Rajbongshi, Apurba
    Rastogi, Archana
    Kumar, Anupam
    Sarin, Shiv K.
    HEPATOLOGY COMMUNICATIONS, 2018, 2 (09) : 1095 - 1110
  • [29] Controversies in Osteoporosis Management: Antiresorptive Therapy for Preventing Bone Loss: When to Use One or Two Antiresorptive Agents?
    Gallagher, J. Christopher
    Tella, Sri Harsha
    CLINICAL OBSTETRICS AND GYNECOLOGY, 2013, 56 (04) : 749 - 756
  • [30] Advances in Osteoporosis Therapy: Focus on Osteoanabolic Agents, Secondary Fracture Prevention, and Perioperative Bone Health
    Paul J. Kostenuik
    Neil Binkley
    Paul A. Anderson
    Current Osteoporosis Reports, 2023, 21 : 386 - 400
12345